Sarah Tasian, MD

Dr. Tasian is researching FLT3 Receptor-Redirected Chimeric Antigen Receptor T Call Immunotherapy for High Risk Pediatric Leukemias.

Many children with high risk acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) are resistant to chemotherapy and will relapse. We are testing new “killer T cell” immunotherapies in specialized leukemia mouse models with the goal of rapid translation into clinical trial testing in children with relapsed/refractory leukemias.